Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 13/20 | 0.54 |
| ▸ | NPY1R | P25929 | 8/20 | 0.54 |
| ▸ | NPY2R | P49146 | 6/20 | 0.54 |
| ▸ | NPY5R | Q15761 | 6/20 | 0.54 |
| ▸ | IL23R | Q5VWK5 | 5/20 | 0.49 |
| ▸ | TFPI | P10646 | 1/20 | 0.48 |
| ▸ | VIPR1 | P32241 | 1/20 | 0.47 |
| ▸ | VIPR2 | P41587 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30361584 | 0.91 | NPY4R (0.57) | NPY4RNPY1RNPY2RNPY5RIL23R | |
| SCHEMBL30773467 | 0.90 | NPY4R (0.55) | NPY4RNPY1RNPY2RNPY5RTFPI | |
| SCHEMBL29754573 | 0.90 | IL23R (0.62) | IL23R | |
| SCHEMBL29530945 | 0.90 | NPY4R (0.65) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL29531034 | 0.88 | NPY4R (0.64) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL29449497 | 0.88 | NPY4R (0.62) | NPY4RNPY1RNPY2RNPY5RVIPR1 | |
| SCHEMBL30361666 | 0.88 | NPY4R (0.63) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL31433352 | 0.87 | NPY4R (0.59) | NPY4RNPY1RNPY2RNPY5RTFPI | |
| SCHEMBL31188458 | 0.87 | NPY4R (0.65) | NPY4RNPY1RNPY2RNPY5R | |
| SCHEMBL30153268 | 0.87 | NPY4R (0.65) | NPY4RNPY1RNPY2RNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022141500-A1 | USE OF CELL PENETRATING PEPTIDE CAPABLE OF COMBINING WITH ACTIVE SUBSTANCE AND PROMOTING EFFICACY OF ACTIVE SUBSTANCE FOR SKINCARE | 妍禾生医科技股份有限公司 | 2022-07-07 | — | — | WO | disclosed |
| EP-4023208-A1 | TOPICAL COMPOSITIONS FOR SKIN COMPRISING A CELL PENETRATING PEPTIDE AND METHODS OF USING THE SAME | ImDerma Laboratories Co., Ltd. (TW) | 2022-07-06 | — | — | EP | disclosed |
| US-20220202943-A1 | TOPICAL COMPOSITIONS FOR SKIN COMPRISING A CELL PENETRATING PEPTIDE AND METHODS OF USING THE SAME | IMDERMA LABORATORIES CO.LTD. (TW) | 2022-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220202943-A1 | TOPICAL COMPOSITIONS FOR SKIN COMPRISING A CELL PENETRATING PEPTIDE AND METHODS OF USING THE SAME | CUTA, NGLY1, SCNN1B | NPY4R 660/4885NPY1R 1069/4885NPY2R 1549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.